USP22 and hepatocellular carcinoma: Taken together, this study demonstrates that USP22 promotes hepatocellular carcinoma growth and inhibits Sorafenib‐induced ferroptosis by deubiquitinating non‐histone substrate CDK11B and histone H2B, respectively.